Type I interferon signals in macrophages and dendritic cells control dengue virus infection: Implications for a new mouse model to test dengue vaccines

Journal of Virology

Volumn 88, Issue 13, 2014, Pages 7276-7285

  Züst, Roland ^a   Toh, Ying Xiu ^a   Valdés, Iris ^b   Cerny, Daniela ^a   Heinrich, Julia ^c   Hermida, Lisset ^b   Marcos, Ernesto ^b   Guillén, Gerardo ^b   Kalinke, Ulrich ^c   Shi, Pei Yong ^d,e   Fink, Katja ^a  

^a AGENCY FOR SCIENCE   (Singapore)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^c INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^d Novartis Institute for Tropical Diseases   (Singapore)

^e WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; DENGUE VIRUS EDIII CAPSID SUBUNIT VACCINE; GAMMA INTERFERON; INTERFERON; INTERFERON RECEPTOR; PLACEBO; UNCLASSIFIED DRUG; CYTOKINE; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DENGUE VIRUS; DENGUE VIRUS 2; DISEASE PREDISPOSITION; FEMALE; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIREMIA; VIRUS TITRATION; ANIMAL; C57BL MOUSE; DENGUE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

ANIMALS; CYTOKINES; DENDRITIC CELLS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNIZATION; INTERFERON TYPE I; INTERFERON-GAMMA; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RNA, VIRAL; VIRUS REPLICATION;

EID: 84901981496     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03827-13     Document Type: Article

References (54)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507. http: //dx.doi.org/10.1038/nature12060.
2. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martinez E, Nathan MB, Pelegrino JL, Simmons C, Yoksan S, Peeling RW. 2010. Dengue: a continuing global threat. Nat. Rev. Microbiol. 8:S7-S16. http://dx.doi.org /10.1038/nrmicro2460.
3. Gubler DJ. 2002. The global emergence/resurgence of arboviral diseases as public health problems. Arch. Med. Res. 33:330-342. http://dx.doi.org /10.1016/S0188-4409(02)00378-8.
4. Simmons CP, Farrar JJ, Chau NvV, Wills B. 2012. Dengue. N. Engl. J. Med. 366:1423-1432. http://dx.doi.org/10.1056/NEJMra1110265.
5. Zompi S, Harris E. 2012. Animal models of dengue virus infection. Viruses 4:62-82. http://dx.doi.org/10.3390/v4010062.
6. Xu M, Hadinoto V, Appanna R, Joensson K, Toh YX, Balakrishnan T, Ong SH, Warter L, Leo YS, Wang CI, Fink K. 2012. Plasmablasts generated during repeated dengue infection are virus glycoproteinspecific and bind to multiple virus serotypes. J. Immunol. 189:5877-5885. http://dx.doi.org/10.4049/jimmunol.1201688.
7. Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, Kondreddi RR, Niyomrattanakit P, Lakshminarayana SB, Goh A, Xu HY, Liu W, Liu B, Lim JY, Ng CY, Qing M, Lim CC, Yip A, Wang G, Chan WL, Tan HP, Lin K, Zhang B, Zou G, Bernard KA, Garrett C, Beltz K, Dong M, Weaver M, He H, Pichota A, Dartois V, Keller TH, Shi PY. 2009. An adenosine nucleoside inhibitor of dengue virus. Proc. Natl. Acad. Sci. U. S. A. 106:20435-20439. http://dx.doi.org/10.1073/pnas.0907010106.
8. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG. 2007. A dengue fever viremia model in mice shows reduction in viral replication and sup-pression of the inflammatory response after treatment with antiviral drugs. J. Infect. Dis. 195:665-674. http://dx.doi.org/10.1086/511310.
9. Zou G, Kukkaro P, Lok SM, Ng JK, Tan GK, Hanson BJ, Alonso S, MacAry PA, Shi PY. 2012. Resistance analysis of an antibody that selectively inhibits dengue virus serotype-1. Antiviral Res. 95:216-223. http: //dx.doi.org/10.1016/j.antiviral.2012.06.010.
10. Orozco S, Schmid MA, Parameswaran P, Lachica R, Henn MR, Beatty R, Harris E. 2012. Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J. Gen. Virol. 93:2152-2157. http://dx.doi.org/10.1099/vir.0.045088-0.
11. Johnson AJ, Roehrig JT. 1999. New mouse model for dengue virus vaccine testing. J. Virol. 73:783-786.
12. Ashour J, Morrison J, Laurent-Rolle M, Belicha-Villanueva A, Plumlee CR, Bernal-Rubio D, Williams KL, Harris E, Fernandez-Sesma A, Schindler C, Garcia-Sastre A. 2010. Mouse STAT2 restricts early dengue virus replication. Cell Host Microbe 8:410-421. http://dx.doi.org/10 .1016/j.chom.2010.10.007.
13. Shresta S, Sharar KL, Prigozhin DM, Snider HM, Beatty PR, Harris E.2005. Critical roles for both STAT1-dependent and STAT1-independent pathways in the control of primary dengue virus infection in mice. J. Immunol. 175:3946-3954. http://dx.doi.org/10.4049/jimmunol.175.6.3946.
14. Prestwood TR, Morar MM, Zellweger RM, Miller R, May MM, Yauch LE, Lada SM, Shresta S. 2012. Gamma interferon (IFN-gamma) receptor restricts systemic dengue virus replication and prevents paralysis in IFNalpha/ beta receptor-deficient mice. J. Virol. 86:12561-12570. http://dx .doi.org/10.1128/JVI.06743-11.
15. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, Harris E.2004. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T-and B-cell-dependent immunity are less critical. J. Virol. 78:2701-2710. http://dx.doi.org/10 .1128/JVI.78.6.2701-2710.2004.
16. Fink K, Lang KS, Manjarrez-Orduno N, Junt T, Senn BM, Holdener M, Akira S, Zinkernagel RM, Hengartner H. 2006. Early type I interferonmediated signals on B cells specifically enhance antiviral humoral responses. Eur. J. Immunol. 36:2094-2105. http://dx.doi.org/10.1002/eji .200635993.
17. Heer AK, Shamshiev A, Donda A, Uematsu S, Akira S, Kopf M, Marsland BJ. 2007. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J. Immunol. 178: 2182-2191. http://dx.doi.org/10.4049/jimmunol.178.4.2182.
18. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. 2001. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14:461-470. http://dx.doi.org/10.1016/S1074-7613(01)00126-1.
19. Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. 2006. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108:3253-3261. http://dx.doi.org/10.1182 /blood-2006-06-027599.
20. Salazar-Mather TP, Lewis CA, Biron CA. 2002. Type I interferons regulate inflammatory cell trafficking and macrophage inflammatory protein 1alpha delivery to the liver. J. Clin. Invest. 110:321-330. http://dx.doi.org /10.1172/JCI15376.
21. Lapenta C, Santini SM, Spada M, Donati S, Urbani F, Accapezzato D, Franceschini D, Andreotti M, Barnaba V, Belardelli F. 2006. IFN-alphaconditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur. J. Immunol. 36: 2046-2060. http://dx.doi.org/10.1002/eji.200535579.
22. + T cell response during cross-priming. J. Immunol. 176:4682-4689. http://dx.doi.org/10.4049/jimmunol.176.8 .4682.
23. Longman RS, Braun D, Pellegrini S, Rice CM, Darnell RB, Albert ML.2007. Dendritic-cell maturation alters intracellular signaling networks, enabling differential effects of IFN-alpha/beta on antigen crosspresentation. Blood 109:1113-1122. http://dx.doi.org/10.1182/blood-2006-05-023465.
24. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L, Azuma YT, Flavell RA, Liljestrom P, Reise Sousa C. 2005. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433: 887-892. http://dx.doi.org/10.1038/nature03326.
25. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, Tough DF. 2006. Enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 176:2074-2078. http://dx.doi.org/10.4049/jimmunol.176.4.2074.
26. Havenar-Daughton C, Kolumam GA, Murali-Krishna K. 2006. The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J. Immunol. 176:3315-3319. http://dx.doi.org/10.4049/jimmunol.176.6.3315.
27. Thompson LJ, Kolumam GA, Thomas S, Murali-Krishna K. 2006. Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. J. Immunol. 177:1746-1754. http://www.jimmunol .org/content/177/3/1746.full.pdf.
28. Aichele P, Unsoeld H, Koschella M, Schweier O, Kalinke U, Vucikuja S.2006. CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. J. Immunol. 176:4525-4529. http://dx.doi.org/10.4049/jimmunol.176.8.4525.
29. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K.2005. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202:637-650. http://dx.doi.org/10.1084/jem.20050821.
30. Valdes I, Bernardo L, Gil L, Pavon A, Lazo L, Lopez C, Romero Y, Menendez I, Falcon V, Betancourt L, Martin J, Chinea G, Silva R, Guzman MG, Guillen G, Hermida L. 2009. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 394:249-258. http://dx.doi.org/10.1016/j.virol.2009.08.029.
31. Marcos E, Gil L, Lazo L, Izquierdo A, Brown E, Suzarte E, Valdes I, Garcia A, Mendez L, Guzman MG, Guillen G, Hermida L. 2013. Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus. Arch. Virol. 158:225-230. http://dx.doi.org/10.1007/s00705-012-1471-z.
32. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. 1999. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8:265-277. http://dx.doi.org/10.1023 /A:1008942828960.
33. Caton ML, Smith-Raska MR, Reizis B. 2007. Notch-RBP-J. signaling controls the homeostasis of CD8+ dendritic cells in the spleen. J. Exp. Med. 204:1653-1664. http://dx.doi.org/10.1084/jem.20062648.
34. Zust R, Dong H, Li XF, Chang DC, Zhang B, Balakrishnan T, Toh YX, Jiang T, Li SH, Deng YQ, Ellis BR, Ellis EM, Poidinger M, Zolezzi F, Qin CF, Shi PY, Fink K. 2013. Rational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques. PLoS Pathog. 9:e1003521. http://dx.doi .org/10.1371/journal.ppat.1003521.
35. Grant D, Tan GK, Qing M, Ng JK, Yip A, Zou G, Xie X, Yuan Z, Schreiber MJ, Schul W, Shi PY, Alonso S. 2011. A single amino acid in nonstructural protein NS4B confers virulence to dengue virus in AG129 mice through enhancement of viralRNAsynthesis. J. Virol. 85:7775-7787. http://dx.doi.org/10.1128/JVI.00665-11.
36. Tan GK, Ng JK, Trasti SL, Schul W, Yip G, Alonso S. 2010. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl. Trop. Dis. 4:e672. http://dx.doi.org/10 .1371/journal.pntd.0000672.
37. Gurukumar KR, Priyadarshini D, Patil JA, Bhagat A, Singh A, Shah PS, Cecilia D. 2009. Development of real time PCR for detection and quantitation of dengue viruses. Virol. J. 6:10. http://dx.doi.org/10.1186/1743-422X-6-10.
38. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR, Harris E. 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 6:e1000790. http://dx.doi.org/10.1371/journal.ppat.1000790.
39. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, Harris E. 2000. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J. Virol. 74:4957-4966. http://dx.doi.org/10.1128/JVI .74.11.4957-4966.2000.
40. Pulendran B. 2004. Modulating TH1/TH2 responses with microbes, dendritic cells, and pathogen recognition receptors. Immunol. Res. 29:187-196. http://dx.doi.org/10.1385/IR:29:1-3:187.
41. Yen YT, Chen HC, Lin YD, Shieh CC, Wu-Hsieh BA. 2008. Enhancement by tumor necrosis factor alpha of dengue virus-induced endothelial cell production of reactive nitrogen and oxygen species is key to hemorrhage development. J. Virol. 82:12312-12324. http://dx.doi.org/10.1128 /JVI.00968-08.
42. Gunther VJ, Putnak R, Eckels KH, Mammen MP, Scherer JM, Lyons A, Sztein MB, Sun W. 2011. A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 29:3895-3904. http://dx.doi.org /10.1016/j.vaccine.2011.03.038.
43. Houghton-Trivino N, Salgado DM, Rodriguez JA, Bosch I, Castellanos JE. 2010. Levels of soluble ST2 in serum associated with severity of dengue due to tumour necrosis factor alpha stimulation. J. Gen. Virol. 91:697-706. http://dx.doi.org/10.1099/vir.0.012971-0.
44. Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE, Shresta S.2013. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog. 9:e1003723. http://dx.doi.org/10 .1371/journal.ppat.1003723.
45. Schlesinger RW. 1977. Dengue viruses. Virol. Monogr. 1977:1-132.
46. Raut CG, Deolankar RP, Kolhapure RM, Goverdhan MK. 1996. Susceptibility of laboratory-bred rodents to the experimental infection with dengue virus type 2. Acta Virol. 40:143-146.
47. Frenz T, Waibler Z, Hofmann J, Hamdorf M, Lantermann M, Reizis B, Tovey MG, Aichele P, Sutter G, Kalinke U. 2010. Concomitant type I IFN receptor-triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara-induced T-cell expansion. Eur. J. Immunol. 40:2769-2777. http://dx.doi.org/10.1002/eji.201040453.
48. Belardelli F, Gresser I. 1996. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today 17:369-372. http://dx.doi.org/10.1016/0167-5699(96)10027-X.
49. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. 2005. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 174:4465-4469. http://dx.doi .org/10.4049/jimmunol.174.8.4465.
50. Braun D, Caramalho I, Demengeot J. 2002. IFN-alpha/beta enhances BCR-dependent B cell responses. Int. Immunol. 14:411-419. http://dx .doi.org/10.1093/intimm/14.4.411.
51. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J.2003. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19:225-234. http: //dx.doi.org/10.1016/S1074-7613(03)00208-5.
52. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, Peters B, Prestwood TR, Sette A, Shresta S. 2009. A protective role for dengue virus-specific CD8+ T cells. J. Immunol. 182:4865-4873. http://dx.doi .org/10.4049/jimmunol.0801974.
53. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. 2012. Protective efficacy of the recombinant, liveattenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559-1567. http://dx.doi .org/10.1016/S0140-6736(12)61428-7.
54. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, Rothman AL, Libraty DH. 2004. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 189: 990-1000. http://dx.doi.org/10.1086/382280.